Clinical trials: Glaucoma Diagnosis
Glaucoma
Efficacy and Safety of the ELIOS Laser in Combined Cataract and Glaucoma Surgery
Glaucoma is an irreversible optic neuropathy. It is the second most common cause of blindness worldwide. Glaucoma can be treated with topical medications (eye drops), laser or surgery.
- Trial name
- ELIOS (NCT06760169)
- Testing
- Surgery with ELIOS laser
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Hôpital Privé de la Baie
Glaucoma, Open-Angle, Ocular Hypertension
Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)
This study will evaluate assessments from the Goniometric Lens compared with those from anterior segment imaging in patients with open-angle glaucoma (OAG) and/or ocular hypertension (OHT).
- Trial name
- NCT01540370
- Testing
- No Treatment
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Allergan
Diabetic Retinopathy, Proliferative Vitreoretinopathy
Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics
The surgically-harvested eye tissue (ie. vitreous-retinal proliferative membrane, outflow pathway, retinas, and pterygium) is a complex tissue responsible for maintaining intraocular homeostasis or mediating ocular pathogenesis.
- Conditions
- Diabetic Retinopathy, Proliferative Vitreoretinopathy, Pterygium, Glaucoma
- Trial name
- Eyesinglecell (NCT04682054)
- Testing
- ocular surgery
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Primary Congenital Glaucoma, Developmental Glaucoma
Ologen® Collagen Matrix in Patients With Primary Congenital Glaucoma Undergoing Trabeculectomy
To the best of Investigator knowledge, no studies to this date have compared the safety and efficacy of ologen® Collagen Matrix in Primary congenital glaucoma (PCG) patients undergoing trabeculectomy.
- Conditions
- Primary Congenital Glaucoma, Developmental Glaucoma, Infantile Glaucoma
- Trial name
- NCT03541551
- Testing
- CTT with ologen® Collagen Matrix, Trab Trab
- Where
- India
- Volunteers
- 44 people
- Sponsor
- L.V. Prasad Eye Institute
Glaucoma, Angle-closure, Primary, Acute
Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure
This is a randomised controlled trial to assess the neuroprotective effect of Cop-1 (Copaxone) in patients with acute primary angle closure (APAC).
- Trial name
- NCT01936129
- Testing
- Copaxone
- Where
- Singapore
- Volunteers
- 196 people
- Sponsor
- Singapore Eye Research Institute
Glaucoma, Intraocular Pressure
Intraocular Pressure Fluctuation in Patients With Glaucoma and in Healthy Patients During Standard Yoga Positions
The purpose of the study is to investigate the IOP difference between normal and glaucomatous eyes using standard ophthalmic tonometry devices while subjects are performing different standard yoga asanas.
- Trial name
- NCT01915680
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Robert Ritch, MD, LLC.
Glaucoma Medication Adherence
The Impact of a Brief Educational Intervention on Glaucoma Adherence
OBJECTIVE Our objective was to determine whether two group educational sessions plus one-on-one eye drop instillation training would improve adherence to glaucoma therapy as measured by pharmacy claims data in a cohort of newly…
- Trial name
- NCT02097979
- Testing
- Glaucoma Educational Intervention
- Where
- Canada
- Sponsor
- Maisonneuve-Rosemont Hospital
Age-Related Macular Degeneration
Five-year Incidence of Age-related Macular Degeneration in the Central Region of Portugal
To assess the five-year incidence of AMD in a population from the central region of Portugal, previously phenotypically characterized.
- Trial name
- AMDIncidencePT (NCT02748824)
- Where
- Portugal
- Volunteers
- 5,996 people, healthy volunteers welcome
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Glaucoma
Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.
In patients with Glaucoma, Xalost S or Xalatan or Taflotan-S are administered for 12 weeks. After 12 weeks, among them, Xalatan administration group are switched to Xalost S or Taflotan-S. Extension study period is 8 weeks.
- Trial name
- NCT04164459
- Testing
- Xalost S, Xalatan, Taflotan-S
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Glaucoma, Ocular Hypertension
A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension
This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P)…
- Trial name
- NCT01525173
- Testing
- 0.1% brimonidine tartrate ophthalmic solution, 0.01% bimatoprost ophthalmic solution, 0.2% hypromellose lubricant eye drops
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Allergan
Glaucoma
SENSIMED Triggerfish
The purpose of the investigation is to investigate the relationship between the study device output and tonometric assessments.
- Trial name
- NCT01319604
- Testing
- SENSIMED Triggerfish, Tonometer
- Where
- 5 sites in Belgium, Denmark and 2 more
- Volunteers
- 59 people
- Sponsor
- Sensimed AG
Glaucoma, Ocular Hypertension
AR-12286 in Combination With Latanoprost
This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).
- Trial name
- NCT01302249
- Testing
- Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%
- Where
- 15 sites in United States
- Volunteers
- 66 people
- Sponsor
- Aerie Pharmaceuticals
Diabetic Macular Edema, Branch Retinal Vein Occlusion
EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
This is a randomized, double-masked, multicenter, study to evaluate the efficacy, safety, and tolerability of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
- Conditions
- Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
- Trial name
- CLEAN (NCT05127525)
- Testing
- IRX-101, Control
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- iRenix Medical, Inc.
Glaucoma, Open-Angle
Ginkgo Biloba and Ocular Blood Flow in Primary Open-angle Glaucoma
Glaucoma is one of the leading causes of blindness. Ginkgo biloba may be part of an effective treatment strategy for glaucoma because it has been shown to improve blood flow, it has antioxidant properties, it can relax smooth…
- Trial name
- NCT02376114
- Testing
- Ginkgo biloba
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Primary Open Angle Glaucoma or Ocular Hypertension
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo
- Trial name
- NCT03233308
- Testing
- Netarsudil Ophthalmic Solution 0.02%
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aerie Pharmaceuticals
Primary Open Angle Glaucoma, Exfoliation Syndrome
24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination
The purpose of this study is to compare the short-term (8 week) mean 24-hour intraocular pressure control and safety of TravTim fixed combination given once in the evening with placebo once in the morning versus TravTim given…
- Trial name
- NCT00331240
- Testing
- travoprost/timolol fixed combination
- Where
- Greece
- Volunteers
- 32 people
- Sponsor
- Aristotle University Of Thessaloniki
Glaucoma, Angle-Closure
Phacotrabeculectomy Versus Phacogoniotomy (PVP) in Advanced Primary Angle-closure Glaucoma
A multicenter, parallel, open, non-inferior randomized controlled trial was conducted to compare the effectiveness and safety of phacotrabeculectomy and phacogoniotomy in the treatment of advanced primary angle closure glaucoma…
- Trial name
- PVP (NCT04878458)
- Testing
- phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy, phacoemulsification with intraocular lens implantation combined with trabeculectomy
- Where
- 2 sites in China
- Volunteers
- 124 people
- Sponsor
- Sun Yat-sen University
Glaucoma, Open-Angle, Cataract Complicated
Evaluation of Phacogoniotomy in Medically-controlled POAG
The goal of this multicenter non-inferiority randomized controlled trial is to compare the efficacy of phacoemulsification with intraocular lens implantation (PEI) combined with goniotomy (GT) and PEI combined with medical…
- Conditions
- Glaucoma, Open-Angle, Cataract Complicated, Goniotomy
- Trial name
- ECO (NCT06201455)
- Testing
- PEI+GT, PEI+MED
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Glaucoma, Ocular Hypertension
Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
The purpose of this study is to determine the efficacy and safety of OPC-1085EL ophthalmic solution in comparison with carteolol long-acting ophthalmic solution in subjects who are insufficiently responsive to carteolol…
- Trial name
- NCT02105285
- Testing
- OPC-1085EL ophthalmic solution, Carteolol long-acting ophthalmic solution
- Where
- Japan
- Volunteers
- 193 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Open-Angle Glaucoma
Diurnal Intraocular Pressure and Peripapillary Retinal Blood Flow in Medically Controlled Open-Angle Glaucoma
Diurnal fluctuations of intraocular pressure (IOP) and peripapillary retinal blood flow may have distinctive patterns in medically well-controlled open-angle glaucoma patients.
- Trial name
- IOPMG (NCT00481208)
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Yonsei University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.